Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab....

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval G., Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr M., Larson, Richard A., Asch, Adam S., Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany N., Bradley, Terrence J., Jeyakumar, Deepa, Wang, Eunice S., Sweet, Kendra, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua F., Sallman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617926/
https://www.ncbi.nlm.nih.gov/pubmed/37703506
http://dx.doi.org/10.1200/JCO.22.02604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617926/
https://www.ncbi.nlm.nih.gov/pubmed/37703506
http://dx.doi.org/10.1200/JCO.22.02604

Ejemplares similares